BDKRB2 and hereditary angioedema: During the last 6 months, all 94 patients included in the study had access through the National HAE Program to home treatment with subcutaneous injection of bradykinin B2-receptor antagonist for acute HAE attacks (icatibant), and 7 (7.4%) had also used pdC1-INH.